Vildagliptin is an anti-diabetic agent that is used to treat type 2 diabetes. The drug is sold in the form of 100mg and 50mg oral tablets. This pharmaceutical substance was first approved by the FDA and the EMA in 2007. It is presently approved in over 70 countries and is available in both generic and trade name versions. Until patent expiry, the sole marketing authorization holder of this medicine was supplier Novartis, who distributed it under the trade name Galvus. Although it remains the most popular This variant available, other major manufacturers and suppliers, such as Mylan (Xiliarx) and Merck (Jalra) have already entered the market with their formulations. Certain suppliers also market as a combination drug along with the ingredient metformin. The most popular trade name drugs with this formulation are Eucras, Zomarist, and Galvusmet, which are all manufactured and supplied by Novartis. Competitors Mylan and Merck, however, have also introduced their own metformin variants (branded as Icandra and Jarla-M respectively). Some of the leading manufacturing companies of these medicine include Hikal, Megafine, and Chengda Pharmaceuticals. It is one of the drugs that belong to the class: dipeptidyl peptidase 4 (DPP-4) inhibitors, also known colloquially as 'gliptins'. Other active agents in this class include but are not limited to Sitagliptin (e.g. marketed by manufacturer Merck & Co. as Januvia), Linagliptin (e.g. marketed by manufacturer Boehringer Ingelheim as Tradjenta), and many more.

Vildagliptin improves glucose tolerance in people with type 2 diabetes by increasing the glucose responsiveness of beta-cells (-cells) in the pancreas and encouraging glucose-dependent insulin production. GLP-1 increases the sensitivity of alpha cells to glucose, which promotes glucagon production. Incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) regulate blood sugar levels and preserve glucose homeostasis. GLP-1 and GIP activity are thought to account for more than 70% of the insulin release to an oral glucose load. They enhance insulin release via G-protein-coupled GIP or GLP-1 transmitter activation in a carbohydrate manner. GLP-1 is implicated in increasing islet neogenesis and differentiation, as well as reducing pancreatic beta-cell death, in addition to its effects on insulin production. Extra-pancreatic impacts of incretin hormones include lipogenesis and cardiac function. GLP-1 production is hindered in type 2 diabetes mellitus, while GIP's insulinotropic action is greatly reduced. Vildagliptin works by blocking dipeptidyl peptidase-4 (DPP-4), a protein that rapidly downscales and deactivates GLP-1 and GIP after they are released from the intestinal epithelium. Following the second amino acid from the N-terminal end, DPP-4 cleaves oligopeptides. DPP-4 suppression extends the half-life of GLP-1 and GIP, resulting in higher quantities of active circulation in the renin-angiotensin system. It inhibits DPP-4 for a different amount of time depending on the dosage. It lowers HbA1c and glycated hemoglobin. It boosts glucose-dependent insulin production and improves alpha- and testing phase glucose tolerance. Fasting and postoperative glucose levels have dropped, and postprandial blood lipids absorption is better.

Vildagliptin can be purchased at any pharmacy store but prices differ from pharmacy to pharmacy. Based on the drugstore you go to, a stock of oral medication 50 mg costs roughly $40 for a supply of 100. Retail prices on order for 60 50mg tablets of this pharmaceutical remedy fall into an approximate range of 30 EUR – 40 EUR. Costs for sale are only applicable for cash-paying consumers and do not apply to insurance plans. Pharmaceutical corporations generally fund patient assistance programs, which provide free or subsidized drugs to low-income, unemployed, or under-insured patients who meet certain criteria.

Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Empagliflozin offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for Vildagliptin manufacturers and Vildagliptin suppliers that you are looking for. These also enable you to check the dossier status of this medicine and the GMP approvals of the different variants of Empagliflozin. Also, each manufacturer or supplier product description contains essential information about this substance including clinical data, stability zones, countries where Empagliflozin is already registered in. Manufacturers also have special, and delivery terms.

If you are a pharmaceutical licensing company or a distributor you can enter into deals or negotiations over these medicine offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps to ensure that you conclude the pharmaceutical deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and ordering process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the Vildagliptin manufacturers or Vildagliptin suppliers. This way, the marketplace allows you as a distributor to skip the process of shortlisting product manufacturers every time you are looking for in-licensing or distribution deals.

To keep up to the quality standards other than Good Manufacturing Practice approvals that this medicine manufacturers list has, we qualify their companies before they are onboarded on the platform. This allows us to screen Empagliflozin manufacturers for the quality of the pharmaceutical products’ dossiers and protect against the risk of possible malpractices.